Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study DOI Open Access
Ariadna Roqué,

Ferran Pérez-Bueno,

Xavier Pozo-Ariza

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 3960 - 3960

Published: April 22, 2025

Triple-negative breast cancer (TNBC) is an aggressive subtype requiring further knowledge of biomarkers to improve targeted therapy. A major resistance mechanism involves stem cells (BCSCs) evading the immune system. Neoadjuvant or adjuvant chemotherapy may alter BCSCs and patients’ response. We conducted a retrospective study including 29 early-stage TNBC patients resistant diagnosed at Catalan Institute Oncology (Girona, Spain) in 2010–2019. obtained 44 paired tumor samples (pre- post-chemotherapy) from Tumor Biobank, assessing BCSC (CD44, CD24, ALDH1), PD-L1, percentages stromal tumor-infiltrating lymphocytes (TILs). Clinicopathological characteristics were also collected. At baseline, 68% tumors had high CD44 expression, 55% showed low CD24 9% ALDH1 91% PD-L1-negative (<1%), 64% percentage TILs. PD-L1 expression significantly increased post-chemotherapy, with 50% initially negative becoming positive (≥1%) (p = 0.006). No significant changes observed markers association was found between baseline post-chemotherapy. median follow-up 58.9 months, 48.3% alive, non-significant favorable trends time progression, disease-free survival, overall survival positivization cohort In conclusion, high-risk after chemotherapy, potentially affecting clinical outcomes. remained stable independent immunogenicity Further studies are needed explore relationship profile, for development new combined therapeutic strategies.

Language: Английский

Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study DOI Open Access
Ariadna Roqué,

Ferran Pérez-Bueno,

Xavier Pozo-Ariza

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 3960 - 3960

Published: April 22, 2025

Triple-negative breast cancer (TNBC) is an aggressive subtype requiring further knowledge of biomarkers to improve targeted therapy. A major resistance mechanism involves stem cells (BCSCs) evading the immune system. Neoadjuvant or adjuvant chemotherapy may alter BCSCs and patients’ response. We conducted a retrospective study including 29 early-stage TNBC patients resistant diagnosed at Catalan Institute Oncology (Girona, Spain) in 2010–2019. obtained 44 paired tumor samples (pre- post-chemotherapy) from Tumor Biobank, assessing BCSC (CD44, CD24, ALDH1), PD-L1, percentages stromal tumor-infiltrating lymphocytes (TILs). Clinicopathological characteristics were also collected. At baseline, 68% tumors had high CD44 expression, 55% showed low CD24 9% ALDH1 91% PD-L1-negative (<1%), 64% percentage TILs. PD-L1 expression significantly increased post-chemotherapy, with 50% initially negative becoming positive (≥1%) (p = 0.006). No significant changes observed markers association was found between baseline post-chemotherapy. median follow-up 58.9 months, 48.3% alive, non-significant favorable trends time progression, disease-free survival, overall survival positivization cohort In conclusion, high-risk after chemotherapy, potentially affecting clinical outcomes. remained stable independent immunogenicity Further studies are needed explore relationship profile, for development new combined therapeutic strategies.

Language: Английский

Citations

0